Perillyl alcohol - intranasal

Drug Profile

Perillyl alcohol - intranasal

Alternative Names: NEO-100; POH

Latest Information Update: 27 May 2016

Price : $50

At a glance

  • Originator NEONC Technologies
  • Developer National Cancer Institute (USA); NEONC Technologies
  • Class Monoterpenes; Small molecules
  • Mechanism of Action Apoptosis stimulants; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Glioblastoma; Glioma
  • Discontinued Cancer

Most Recent Events

  • 01 Apr 2016 Phase-I/II clinical trials in Glioma (Recurrent, Late-stage disease, Second-line therapy or greater) in USA (Intranasal) (NCT02704858)
  • 05 Mar 2016 Neonc Technologies plans a phase I/II trial for Glioma (Second-line therapy or greater) in USA (NCT02704858)
  • 12 Feb 2013 Clinical trials in Glioblastoma (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top